Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

Wegovy clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 20 trials in our Canada, USA, China, UK, South Korea, Poland, Australia, Spain, Switzerland, Denmark and Japan registers that name Wegovy as an intervention. Synced 9 Nov 2026
20Current trials
9Recruiting now
19Lead sponsors
11Country registers
At a glance

Wegovy is named as an intervention in 20 current clinical trials in our Canada, USA, China, UK, South Korea, Poland, Australia, Spain, Switzerland, Denmark and Japan registers. 9 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Novo Nordisk A/S (2). The most-studied condition is Obesity.

Patient leaflets for Wegovy

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting945%
  • Not yet open525%
  • Active, closed525%
  • By invitation15%

Trials by phase

  • Phase 4630%
  • Phase 3315%
  • Phase 1315%
  • Phase 2315%
  • Observational210%
  • Not applicable210%
  • Phase 2/315%
01

Clinical trials of Wegovy

20 trials
StudyPhaseStatusLead sponsorRegisters
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
NCT06396416 · ClinicalTrials.gov ↗ · Obesity, Chronic Kidney Disease
Phase 4 Recruiting Western University, Canada Canada
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
NCT06852391 · ClinicalTrials.gov ↗ · Obesity (Disorder)
Phase 4 Recruiting McMaster University Canada
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
NCT07592546 · ClinicalTrials.gov ↗ · Class I/II Obesity
Phase 4 Recruiting Alain Dagher Canada
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
NCT07036172 · ClinicalTrials.gov ↗ · Obesity Control
Phase 3 Recruiting Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd China
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975 · ClinicalTrials.gov ↗ · Obesity/Overweight in Adult
Phase 3 Recruiting Gan & Lee Pharmaceuticals China
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
NCT06073184 · ClinicalTrials.gov ↗ · Endometrial Cancer, Atypical Hyperplasia, Fertility Perservation
Phase 2 Recruiting GynOncTrials Canada
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
NCT06830343 · ClinicalTrials.gov ↗ · Overweight or Obesity
Phase 1 Recruiting CSPC Baike (Shandong) Biopharmaceutical Co., Ltd China
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
NCT07673900 · Overweight and/or Obesity
Phase 1 Recruiting Terrestrial Bio, Inc USA
Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies
NCT07732426 · ClinicalTrials.gov ↗ · Food Addiction Tendency, Obesity, Overweight
Not applicable Recruiting Seoul National University Hospital South Korea
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
NCT07617155 · ClinicalTrials.gov ↗ · Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing
Phase 4 Not yet open Peking Union Medical College Hospital China
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
NCT07858331 · ClinicalTrials.gov ↗ · Obesity, Chronic Kidney Disease, Chronic Renal Disease
Phase 4 Not yet open Kristin Clemens Canada
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
NCT06913023 · ClinicalTrials.gov ↗ · Kidney Transplant Recipient
Phase 2/3 Not yet open University Health Network, Toronto Canada
Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
NCT07909889 · ClinicalTrials.gov ↗ · Breast Cancer (Early Breast Cancer), Obesity
Phase 2 Not yet open Aarhus University Hospital Denmark
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
NCT07621640 · ClinicalTrials.gov ↗ · Obesity, Metabolic Syndrome, Brown Adipose Tissue
Not applicable Not yet open Hallym University South Korea
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
NCT07055607 · Obesity
Observational By invitation Novo Nordisk A/S UK, Spain, Switzerland
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
NCT06908694 · ClinicalTrials.gov ↗ · Prostate Cancer
Phase 4 Active, closed Hamilton Health Sciences Corporation Canada
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979 · Obesity
Phase 3 Active, closed Kailera UK, USA, Poland, Australia
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098 · Obesity
Phase 2 Active, closed Regeneron Pharmaceuticals USA
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT06745284 · Obesity
Phase 1 Active, closed Boehringer Ingelheim USA
Special Use - Results Surveillance on Long-term Use With Wegovy®
NCT06283667 · ClinicalTrials.gov ↗ · Obesity
Observational Active, closed Novo Nordisk A/S Japan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Wegovy

24 conditions
Obesity10Chronic Kidney Disease2Overweight and/or Obesity1Hypertriglyceridemia Induced Acute Pancreatitis1Recurrent Acute Pancreatitis1Pancreatitis Relapsing1Hypertriglyceridemia1Overweight or Obesity1Obesity/Overweight in Adult1Obesity Control1Breast Cancer (Early Breast Cancer)1Kidney Transplant Recipient1
All 24 conditions
Condition (as registered)Trials
Obesity10
Chronic Kidney Disease2
Overweight and/or Obesity1
Hypertriglyceridemia Induced Acute Pancreatitis1
Recurrent Acute Pancreatitis1
Pancreatitis Relapsing1
Hypertriglyceridemia1
Overweight or Obesity1
Obesity/Overweight in Adult1
Obesity Control1
Breast Cancer (Early Breast Cancer)1
Kidney Transplant Recipient1
Obesity (Disorder)1
Chronic Renal Disease1
CKD1
Class I/II Obesity1
Prostate Cancer1
Endometrial Cancer1
Atypical Hyperplasia1
Fertility Perservation1
Metabolic Syndrome1
Brown Adipose Tissue1
Food Addiction Tendency1
Overweight1
05

Related compounds

06

Questions about Wegovy trials

How many clinical trials are testing Wegovy?

20 current trials in our Canada, USA, China, UK, South Korea, Poland, Australia, Spain, Switzerland, Denmark and Japan registers name Wegovy as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Wegovy trials recruiting patients?

Yes. 9 of the 20 trials are recruiting: 4 with sites in Canada, 1 with sites in USA, 3 with sites in China and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Wegovy clinical trials?

Novo Nordisk A/S (2), Kailera (1), Boehringer Ingelheim (1) and Terrestrial Bio, Inc (1), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Wegovy works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Wegovy works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Wegovy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.